Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EUROBEAT Study of empagliflozin in early diabetic kidney disease
jRCTs051200147Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis comparing Empagliflozin with Placebo (2 arms). Primary endpoints: Change from baseline in urinary albumin excretion and Change from baseline in urinary L-FABP excretion. Started Jun 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on jRCTs051200147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051200147.